Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy. Issue 12 (29th June 2021)

• Record Type: Journal Article
• Authors: Wang, Chenyu; Barton, Joshua; Kyle, Kain; Ly, Linda; Barnett, Yael; Hartung, Hans-Peter; Reddel, Stephen W; Beadnall, Heidi; Taha, Marinda; Klistorner, Alexander; Barnett, Michael Harry
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 92:Issue 12(2021)
• Page Start: 1319
• Page End: 1324
• Publication Date: 2021-06-29
• Subjects: multiple sclerosis; Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2021-326164
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Objective: To investigate potential neuroprotective and pro-remyelinating effects of alemtuzumab in multiple sclerosis (MS), using the visual pathway as a model. Methods: We monitored clinical, multifocal visual evoked potential (mfVEP) and MRI outcomes in 30 patients commencing alemtuzumab for relapsing MS, and a reference group of 20 healthy controls (HCs), over 24 months. Change in mfVEP latency was the primary endpoint; change in optic radiation (OR) lesion diffusion metrics and Mars letter contrast sensitivity over the course of the study were secondary endpoints. Results: In patients, we observed a mean shortening of mfVEP latency of 1.21 ms over the course of the study (95% CI 0.21 to 2.21, p=0.013), not altered by correction for age, gender, disease duration or change in OR T2 lesion volume. Mean mfVEP latency in the HC group increased over the course of the study by 0.72 ms (not significant). Analysis of chronic OR T2 lesions (patients) showed an increase in normalised fractional anisotropy and axial diffusivity between baseline and 24 months (both p<0.01). Mean Mars letter contrast sensitivity was improved at 24 months vs baseline (p<0.001), and driven by an early improvement, in both patients and HC. Conclusion: We found evidence of partial lesion remyelination after alemtuzumab therapy, indicating either natural restoration in the context of a 'permissive' local milieu; or potentially an independent, pro-reparative mechanism of action. The visual system presents a unique opportunity to study function-structure specific effects of therapy and inform the design of future phase 2 MS remyelination trials.